The predicted lifetime costs and health consequences of calcium and vitamin D supplementation for fracture prevention—the impact of cardiovascular effects

Osteoporosis International

Volumn 27, Issue 6, 2016, Pages 2089-2098

  Hagen, G ^a,b   Wisloff T ^c,d   Kristiansen, I S ^d,e  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Calcium; Cardiovascular; Cost effectiveness; Fracture; Osteoporosis; Primary prevention

Indexed keywords

CALCIUM; VITAMIN D;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; FEMALE; FRACTURE; HEALTH; HIP FRACTURE; HUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK; RISK ASSESSMENT; SIMULATION; SPINE FRACTURE; VITAMIN SUPPLEMENTATION; WRIST FRACTURE; ADMINISTRATION AND DOSAGE; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; DIETARY SUPPLEMENT; ECONOMICS; RISK FACTOR;

AGED; CALCIUM, DIETARY; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIETARY SUPPLEMENTS; FEMALE; FRACTURES, BONE; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; VITAMIN D;

EID: 84957593372     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-016-3495-9     Document Type: Article

References (51)

1. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8(1–2):136
2. Hansen L, Mathiesen AS, Vestergaard P, Ehlers LH, Petersen KD (2013) A health economic analysis of osteoporotic fractures: who carries the burden? Arch Osteoporos 8(1–2):126
3. Boonen S, Rizzoli R, Meunier PJ, Stone M, Nuki G, Syversen U, Lehtonen-Veromaa M, Lips P, Johnell O, Reginster JY (2004) The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 15(7):511–519
4. Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75(4):392–396
5. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57
6. Avenell A, Mak JC, O’Connell D (2014) Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev 4:CD000227
7. Hiligsmann M, Ben Sedrine W, Bruyere O, Evers SM, Rabenda V, Reginster JY (2014) Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. European journal of public health. doi:10.1093/eurpub/cku119
8. Li K, Kaaks R, Linseisen J, Rohrmann S (2012) Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart (British Cardiac Society) 98(12):920–925
9. Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, Gamble GD, Grey A, Reid IR (2008) Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ (Clinical research ed) 336(7638):262–266
10. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (Clinical research ed) 341:c3691
11. Michaelsson K, Melhus H, Warensjo Lemming E, Wolk A, Byberg L (2013) Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ (Clinical research ed) 346:f228
12. Michaelsson K, Wolk A, Langenskiold S, Basu S, Warensjo Lemming E, Melhus H, Byberg L (2014) Milk intake and risk of mortality and fractures in women and men: cohort studies. BMJ (Clinical research ed) 349:g6015
13. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR (2011) Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ (Clinical research ed) 342:d2040
14. Abrahamsen B, Sahota O (2011) Do calcium plus vitamin D supplements increase cardiovascular risk? BMJ (Clinical research ed) 342:d2080
15. Heaney RP, Kopecky S, Maki KC, Hathcock J, Mackay D, Wallace TC (2012) A review of calcium supplements and cardiovascular disease risk. Adv Nutr (Bethesda, Md) 3(6):763–771
16. Rojas-Fernandez CH, Maclaughlin EJ, Dore NL, Ebsary S (2012) Assessing the potential adverse consequences of supplemental calcium on cardiovascular outcomes: should we change our approach to bone health? Ann Pharmacother 46(5):696–702
17. Nordin BE, Lewis JR, Daly RM, Horowitz J, Metcalfe A, Lange K, Prince RL (2011) The calcium scare—what would Austin Bradford Hill have thought? Osteoporos Int 22(12):3073–3077
18. Prince RL, Nordin C, Lewis JR, Metcalfe A, Daly RM (2012) Problems with epidemiological approach and conclusions. Heart (British Cardiac Society) 98(23):1751, author reply 1751–1752
19. Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, Anderson GL, Chlebowski RT, Manson JE, Van Horn L, Vitolins MZ, Datta M, LeBlanc ES, Cauley JA, Rossouw JE (2013) Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int 24(2):567–580
20. Rothman KJ (2010) Curbing type I and type II errors. Eur J Epidemiol 25(4):223–224
21. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359–2381
22. Hagen G, Wisløff T, Falch J, Lofthus C, Frihagen F, Wensaas KA, Granum L, Nevjar J, Kristiansen IS, Klemp M (2011) Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway. Rapport fra Kunnskapssenteret vol 10–2011. Kunnskapssenteret http://www.kunnskapssenteret.no/Publikasjoner/Efficacy+and+cost-effectiveness+of+alendronate+for+the+prevention+of+fractures+in+postmenopausal+women+in+Norway.12475.cms
23. Wisloff T, Hagen G, Klemp M (2014) Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics 32(6):601–612
24. Wisloff T, Selmer RM, Halvorsen S, Fretheim A, Norheim OF, Kristiansen IS (2012) Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease—a cost-effectiveness analysis. BMC Cardiovasc Disord 12:26
25. Boyd CM, Singh S, Varadhan R, Weiss CO, Sharma R, Bass EB, Puhan MA (2012) Methods for benefit and harm assessment in systematic reviews. Methods research report (Prepared by Johns Hopkins University Evidence-based Practice Centre under contract No. 290-2007-10061-I). AHRQ publication No. 12 (13)-EHC150-EF. Rockville MD: Agency for healthcare research and quality, November 2012
26. Burstrom K, Johannesson M, Diderichsen F (2001) Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 55(1):51–69
27. Ara R, Brazier JE (2010) Populating an economic model with health state utility values: moving toward better practice. Value Health 13(5):509–518
28. Wisloff T, Selmer RM, Halvorsen S, Kristiansen IS (2008) Norwegian Cardiovascular Disease Model (NorCaD) – a simulation model for estimating health benefits and cost consequences of cardiovascular interventions. http://www.kunnskapssenteret.no/publikasjoner/norwegian-cardiovascular-disease-model-norcad-a-simulation-model-for-estimating-health-benefits-and-cost-consequences-of-cardiovascular-interventions
29. Prestmo A, Hagen G, Sletvold O, Helbostad JL, Thingstad P, Taraldsen K, Lydersen S, Halsteinli V, Saltnes T, Lamb SE, Johnsen LG, Saltvedt I (2015) Comprehensive geriatric care for patients with hip fractures: a prospective, randomised, controlled trial. The Lancet 385:1623–1633
30. Recommendations for the economic evaluation of new interventions in the Norwegian health sector. (2012). The Norwegian Directorate of Health, vol IS-1985. Oslo, Norway
31. Health Effects in Economic Analyses (2007). The Norwegian Directorate of Health, vol IS-1435. Oslo, Norway
32. Briggs A, Claxton K, Schulpher M (2006) Decision Modelling for Health Economic Evaluation. Handbooks in Health Economic Evaluation. Oxford University Press, New York
33. Xiao Q, Murphy RA, Houston DK, Harris TB, Chow WH, Park Y (2013) Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med 173(8):639–646
34. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C (2014) Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 1:CD007470
35. Vestergaard P, Rejnmark L, Mosekilde L (2007) Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int 18(12):1583–1593
36. Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD (2011) Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int 22(9):2439–2448
37. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202–210
38. Weinstein M, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce B (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices - Modeling studies. Value Health 6(1):9–17
39. Si L, Winzenberg TM, Palmer AJ (2014) A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol 25, pp 51–60
40. Willis MS (2002) The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden. Int J Technol Assess Health Care 18(4):791–807
41. Ethgen O, Hiligsmann M, Burlet N, Reginster JY (2015) Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol 73. Oslo, Norway, p 48
42. Stoen RO, Nordsletten L, Meyer HE, Frihagen JF, Falch JA, Lofthus CM (2012) Hip fracture incidence is decreasing in the high incidence area of Oslo, Norway. Osteoporos Int 23(10):2527–2534
43. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20–26
44. Lofthus CM, Frihagen F, Meyer HE, Nordsletten L, Melhuus K, Falch JA (2008) Epidemiology of distal forearm fractures in Oslo, Norway. Osteoporos Int 19(6):781–786
45. Drageset J, Eide GE, Ranhoff AH (2013) Mortality in nursing home residents without cognitive impairment and its relation to self-reported health-related quality of life, sociodemographic factors, illness variables and cancer diagnosis: a 5-year follow-up study. Qual Life Res 22(2): 317–325
46. Morin S, Lix LM, Azimaee M, Metge C, Majumdar SR, Leslie WD (2012) Institutionalization following incident non-traumatic fractures in community-dwelling men and women. Osteoporos Int 23(9):2381–2386
47. Peasgood T, Herrmann K, Kanis JA, Brazier JE (2009) An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 20(6):853–868
48. Nowels D, McGloin J, Westfall JM, Holcomb S (2005) Validation of the EQ-5D quality of life instrument in patients after myocardial infarction. Qual Life Res 14(1):95–105
49. Lee HY, Hwang JS, Jeng JS, Wang JD (2010) Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke 41(4):739–744
50. Kontodimopoulos N, Argiriou M, Theakos N, Niakas D (2011) The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure. Eur J Health Econ 12(4):383–391
51. Makai P, Beckebans F, van Exel J, Brouwer WB (2014) Quality of life of nursing home residents with dementia: validation of the German version of the ICECAP-O. PLoS One 9(3):e92016